Argos Therapeutics, Inc. (ARGS) Stock Price Up 0%

Argos Therapeutics, Inc. (NASDAQ:ARGS) rose 0% on Monday . The company traded as high as $0.21 and last traded at $0.20. Approximately 4,735,914 shares traded hands during trading, an increase of 101% from the average daily volume of 2,352,781 shares. The stock had previously closed at $0.20.

Separately, Zacks Investment Research downgraded Argos Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating and three have given a hold rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $4.13.

The company has a debt-to-equity ratio of -1.46, a quick ratio of 2.29 and a current ratio of 2.29.

A hedge fund recently bought a new stake in Argos Therapeutics stock. Wasatch Advisors Inc. acquired a new position in Argos Therapeutics, Inc. (NASDAQ:ARGS) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned about 1.21% of Argos Therapeutics at the end of the most recent reporting period. 29.17% of the stock is owned by institutional investors and hedge funds.

WARNING: “Argos Therapeutics, Inc. (ARGS) Stock Price Up 0%” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply